JAMA Netw Open. 2026 Jul 1;9(7):e2623280. doi: 10.1001/jamanetworkopen.2026.23280. ABSTRACT IMPORTANCE: Buprenorphine-naloxone and extended-release (XR) naltrexone are both efficacious medications for opioid use disorder that reduce unregulated opioid use and improve opioid cravings and treatment retention. While prior comparative effectiveness studies demonstrated superiority of buprenorphine-naloxone over XR naltrexone for relapse and treatment retention, the comparative effectiveness […]